帕潘立酮与利培酮用于精神分裂症的对比分析  

A clinical controlled study on schizophrenia treated with paliperidone-ER and risperidone

作　　者：龚昌海[1] 

机构地区：[1]攀枝花市第三人民医院精神科,四川省攀枝花617061

出　　处：《中国基层医药》2011年第17期2339-2340,共2页Chinese Journal of Primary Medicine and Pharmacy

摘　　要：目的探讨帕潘立酮与利培酮片治疗精神分裂症的效果和不良反应。方法60例精神分裂症患者随机分为观察组和对照组各30例，分别给予帕潘立酮与利培酮治疗，疗程8周。分别于治疗前和治疗1、2、4和8周采用阳性与阴性症状量表（PANSS）评定疗效；以治疗中出现的症状量表评定不良反应。结果治疗后两组PANSS计分均比治疗前显著下降（均P〈0．01）；观察组阴性症状计分在治疗4周与8周时明显比对照组更低（均P〈0．05）。观察组显效率（70％）明显高于对照组（47％），两组有效率（90％与80％）差异无统计学意义（P〉0．05）。结论帕潘立酮是安全有效的抗精神病药物，对阴性症状的改善尤为显著。Objective To compare the efficacy and side effects of paliperidone-ER and risperidone in trea- ting schizophrenia. Methods 60 patients of schizophrenia were treated with paliperidone-ER（ n = 30） or risperldone （n = 30） randomly, for 8 weeks. The efficacy was assessed with the positive and negative symptoms scale （PANSS）, and the safety was assessed with treatment emergent symptoms scale before treatment and at the ends of week 1,2,4 and 8 treatments,respectively. Results The PANSS scores of two groups were significantly decreased after the patients received the drug treatment. Paliperidone-ER group showed lower negative symptom score at week 4 and 8 than risperidone group. The efficacy of study group was significantly higher than that of control group. Conclusion Pali- peridone-ER was effective and safe antipsychotic drug with significant improvement compared with risperidone in negative symptoms.

关 键 词：帕潘立酮 利培酮 精神分裂症 

分 类 号：R74[医药卫生—神经病学与精神病学]